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ABSTRACT 
Bacterial Vaginosis (BV) is the leading cause of vaginal discharge. Because of its big surface area, 
wealthy blood supply, avoidance of the first-pass effect and high permeability to many drugs, the 
vagina offers a promising location for local impact as well as systemic drug delivery. In situ gels 
give several benefits, such as ease of administration in the respective body cavities, elevated 
spreadability at certain temperatures, reduced administration frequency, improved patient 
compliance and comfort compared to standard dosage forms. Tinidazole (TNZ) can give effective 
treatment over the BV. In situ gel of TNZ containing polaxomer 407and HPMC E100 or carbopol 
941NF was optimized on the basis of various evaluation parameters. Gelation temperature (Tgel) 
and pH of all batches was found in range of 36.6 to38.0 ºC and 4.20 to 5.03, viscosity was found in 
range of 1100-2050 cps at 25ºC and 4800-6530 cps at 37ºC. The Spredability was found in range 
of 16-20 cm. From these evaluation parameters we selected best combination for the 
mucoadhesive property, antimicrobial study, in vitro drug release and for HET CAM irritation 
study. The optimized formulation gives satisfactory results. In this study we also compare the 
performance of two mucoadhesive polymer. Based on maximum desirability and cost 
effectiveness, in situ vaginal gel containing 20% polaxomer and 0.5% HPMC E100 could be 
considered as a highly promising treatment for bacterial vaginosis. 
KEYWORDS: Bacterial Vaginosis, Gel, In situ gel, Thermosensitive gel, Tinidazole, Vaginal drug 
delivery. 
INTRODUCTION 
Vaginal infection is wide and over 80% of 
females experience such illnesses during their 
lifetime[1]. Vaginitis is an exceptionally basic 
gynecological issue in ladies of all age gatherings. 
There are three sorts of infectious vaginitis: 
candidiasis, trichomoniasis and bacterial vaginosis[2]. 
Vaginitis is generally achieved by single 
microorganism or multiple realizing mixed vaginal 
infections. Around 30% of all instances of vaginitis 
are brought about by concurrent contaminations 
with in any event at least two pathogens and if not 
treated well, there are odds of sexually transmitted 
disease[3].In females of childbearing age, bacterial 
vaginosis (BV) is the most common cause of vaginal 
discharge. A thin homogeneous white discharge, a 
vaginal pH higher than 4.5, an ideal amine test, and 
the existence of clue cells microscopically 
characterize it. There is an increase in the 
concentration and incidence of organisms including 
Gardnerella vaginalis, Mycoplasma hominis and 
anaerobic bacteria such as Peptostreto cocci, 
Prevotella spp. and Mobiluncus spp. in vaginal flora 
and significant change in the ordinary lactobacilli 
(LB) dominant vaginal flora with hydrogen peroxide 
manufacturing to flora with significantly reduced LB 
figures[4]. 
The vagina provides a promising site for local 
effect as well as systemic drug delivery because of its 
large surface area, rich blood supply, avoidance of the 
first-pass effect, relatively high permeability to many 
drugs and self-insertion[5]. However, due to the wide 
inter-individual variation influencing some 
physiological variables such as pH and the existence 
of limited vaginal secretions which depends on age 
and menstrual cycles, the vaginal route has not been 
widely utilized. Although different options are 
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currently being researched, only limited number of 
vaginal delivery systems are available in market[6] 
such as creams, foams, gels, irrigations, tablets, which 
have certain constraints such as leakage, messiness 
and comparatively poor residence time due to the 
vaginal tract's self-cleaning action and often require 
repeated daily doses to maintain the intended 
therapeutic effect[5]. Despite the fact that traditional 
system aids to control vaginal infections, effective 
treatment isn't carried out absolutely due to 
distinctly dynamic vaginal morphology and 
pharmacokinetics of drugs. There is also a need to 
establish a novel system to enhance local residence 
time of formulation and enhance therapeutic action 
against vaginitis. Before administration, in situ 
forming gel structures are liquid aqueous solutions 
but it gets convert into gel under physiological 
conditions[7]. 
In 1967 Tinidazole (TNZ), 1-[2-(ethylsulfonyl) ethyl]-
2-methyl-5-nitroimidazole, was first implemented for 
the therapy of trichomonas vaginalis infections[8]. 
Oral metronidazole has long been founded in the 
treatment of BV as an efficient therapy. But it gives 
various GI side effects. Nowadays metronidazole and 
clindamycin intravaginal preparations are commonly 
used for the therapy of bacterial vaginosis. TNZ also 
proves effectiveness in BV therapy. Cure rates are 
analogous to metronidazole, but there has been no 
evidence of clinical superiority. TNZ, however, has a 
more favorable side effect profile, particularly with 
better gastrointestinal tolerability and less metallic 
taste, both of which are often involved in bad 
adherence to metronidazole treatment[4]. TNZ is 
effective against protozoa including T. vaginalis, E 
histolytica and G lamblia. It also has in vitro activity 
against several anaerobic bacteria including 
bacteriods, fusobacterium, and clostridium spp. Two 
comparative in vitro research showed minor 
improved in vitro activity against G. vaginalis with 
TNZ compared to metronidazole[9]. Khushbu S. Patel 
et al, formulate the ion as well as thermo sensitive in 
situ gel of TNZ for the treatment of periodontitis 
which are applied on the dental cavity[10]. 
The use of appropriate polymers to formulate 
in situ gel would make them more acceptable and 
convenient drug delivery system [11]. In situ gels give 
several benefits, such as ease of administration in the 
required body cavities, elevated spreadability at 
certain temperatures, reduced administration 
frequency, improved patient compliance and comfort 
compared to standard dosage forms[12]. There are 
numerous possible mechanisms leading to in situ gel 
formation such as ionic cross linkage, solvent 
exchange, UV irradiation, pH or temperature changes 
[13]. A synthetic triblock copolymer consisting of 
polyoxyethylene and polyoxypropylene that exhibits 
thermoresponsive behavior in aqueous solutions is 
Poloxamer (PLX) that was selected to prepare in situ 
gel formulation. They have great compatibility with 
extended release of the active ingredient. 
Formulation of in situ gel with thermosensitive 
polymer having low mucoadhesive property to 
increase the mucoadhesive property polymer like 
HPMC or carbopol was added to enhance the 
mucoadhesive and mechanical characteristics of in 
situ gel formulations and ensure long residence time 
[14]. 
In this article formulation and evaluation of 
thermosensitive and mucoadhesive in situ gel of TNZ 
is done to avoid hepatic first-pass metabolism, a 
reduction in the incidence and severity of 
gastrointestinal side-effects. This in situ gel is directly 
applied to the vaginal cavity for the treatment of BV. 
In situ gel has broad drug absorption peak and a 
longer drug residence time as compared to 
conventional dosage form. Therefore, in this 
proposed research work, in situ gel of TNZ was 
developed which was further characterized and 
evaluated for its antimicrobial efficacy. 
MATERIAL AND METHODS 
Material 
TNZ was gifted by BDH Industry Ltd., 
Kandivali (east), Mumbai. HPMC was procured as a 
gift sample from Colorcon, Goa. Carbopol 941 NF was 
procured from BF Goodrich Co., Breckville Road, 
Cleveland, OH. Pluronic F127 NF Prill (Polaxomer 
407) was obtained from BASF Corporation, Mount 
Olive, New Jersey. Preservative benzalkonium 
chloride (0.01% w/w) other chemicals and solvents 
were procured from licensed vendors of 
pharmaceutical grades. 
Preparation of simulated vaginal fluid 
The simulated vaginal fluid (SVF) was 
prepared by mixing various ingredients such as 
3.51gL-1 of NaCl, 1.40 gL-1of KOH, 0.222 gL-1of 
Ca(OH)2, 0.018 gL-1of bovine serum albumin, 2 gL-1of 
lactic acid, 1 gL-1of acetic acid, 0.16 gL-1of glycerol, 0.4 
gL-1of urea and 5 gL-1of glucose. pH of the mixture 
was adjusted to 4.5 ± 0.02 by using 0.1 N Acetic 
acid[15]. 
Preparation of in Situ gel of the TNZ 
In situ gel of TNZ was prepared by dissolving 
various polymers. Polaxomer 407 (pluronic F127) 
was dissolved in water by using “cold method” at 0-
4⁰C.Carbopol 941 NF/ HPMC E100 was dissolved 
separately in water. The two solutions were mixed by 
continuous stirring and were sonicated for 15 min. 
The accurate amount of drug (0.75%) was weighed 
and dispersed in the above polymeric solution. Lastly 
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preservative was added and sonicated for 15 min and 
was stored below 25⁰C.PH resembles the formulation 
containing polaxomer 407 and HPMC E100 and PC 
resemble the formulation containing polaxomer 407 
and carbopol 941NF. Various trials have been carried 
out for the formulation of the in situ gel of TNZ. The 
formulation compositions of some batches are 
depicted in (Table 1). 
Table 1: Formulation composition 
Batch 
No 
Excipients Concentration 
Polaxomer 407 
(%w/w) 
Carbopol 
941NF (%w/w) 
HPMC E100 
(%w/w) 
Preservativ 
(%w/w) 
PH1 19 - 0.5 0.01 
PH2 20 - 0.5 0.01 
PH3 21 - 0.5 0.01 
PC1 20 0.1 - 0.01 
PC2 21 0.1 - 0.01 
PC3 22 0.1 - 0.01 
Characterization of in situ gel  
Interaction studies (Drug excipients 
compatibility study) 
Compatibility study of drug excipients was 
conducted to check compatibility between drug and 
polymers. Studies of compatibility with drug 
excipients were conducted using fourier transform 
infrared spectrophotometer (FT-IR) (JASCO FT / IR-
4100). Liquid solutions and the physical mixture of 
HPMC E100, carbopol 941 NF and TNZ were 
prepared individually and in combination. To study 
interactions between distinct components, both 
spectra were compared for possible changes[10]. 
Appearance  
For color, odor and presence of suspended 
particulate matter, if any, the formulations were 
closely noted. By observing them against a dark and 
white background, the clarity of the solutions was 
further evaluated. From the observations 
formulations have been classified as turbid (-), 
slightly turbid (+), clear and transparent (+ +)[16]. 
pH evaluation 
The formulation pH was recorded using a pH 
meter (Mettler Instruments, Germany). Triplicate 
experiments were conducted[17]. 
Clarity and refractive index 
The clarity of the formulations after and 
before gelling was determined alternately against 
white and black backgrounds by visual examination 
of the formulations under light. The Abbe's 
refractometer was used to determine the refractive 
indexes of the formulations. The Na Light 
monochromatic lamp was switched on and heated for 
5 min. between illuminating and measuring prism, 1-
2 drop of liquid was placed, the lower case of prism 
was closed. To align the X-Mark in the eye piece with 
the shadow boundary, the rotating knob was used to 
separate the dark and bright region seen in the field 
of view. The scale refractive index has been 
registered[17]. 
Drug content 
About 1 mL of gel was dissolved in100 mL of 
phosphate buffer pH 4.0. After continuous stirring, it 
was then filtered and evaluated at 318 nm by UV 
spectrophotometer after appropriate dilution [18]. The 
experiment was repeated three times for each 
formulation. 
Gelling temperature  
2 mL of the formulation was placed in a test 
tube immersed in a water bath with a temperature 
control of 4°C. The bath temperature gradually 
increased with 1°C. At each temperature, the sample 
was permitted to equalize. The sample was examined 
with a 90° angle by tilting the test tube. The 
temperature at which the gel transition occurred was 
observed as the temperature of gelation stated when 
meniscus would no longer move after the test tube 
had been tilted. Repeat the experiment in triplicate 
and record an average of three readings [19]. 
Viscosity  
A programmable Viscometer (Brookfield, 
RVDV pro II, USA) was used to determine the 
viscosity of the liquid formulations at 25°C and the 
preformed gels at 37°C. 5mL of formulation was 
transmitted to the sample cell, which was closely 
positioned within a tiny volume sample adaptor, to 
determine the solution viscosity. The guard leg was 
put around the adaptor by constantly stirring the 
sample. The sample viscosity at various rotations per 
min (RPM) ranging from 0.5 to 100 RPM at 25°C 
temperature was evaluated. The formulations were 
balanced at a temperature of 37°C and 25°C for 24 h 
to determine gel viscosity at 37°C and 25°C. The gels 
viscosity was determined using a spindle no. 7 of 
brookfield viscometer. The motion of the helipad was 
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regulated to prevent the spindle from touching any 
portion of the sample holder, particularly the bottom. 
Viscosity values were observed at each RPM. The test 
was repeated three times for the same gel sample, 
and the average reading was observed [20]. 
Spreadability 
A sample of 0.5 g of each formulation was 
placed between two slides (separated into 5 mm 
squares) and left for about 5 min at room 
temperature (25-30⁰ C)where no further spread was 
expected. Spread circle diameters were measured in 
cm and taken for spreadability as comparison values. 
The findings acquired are average of three 
determinations[21]. 
Mechanical Properties of Polymer Solutions 
(Textural analysis) 
Textural assessment was conducted using 
Texture Pro CT V1.7 Build 29 software (Brookfield) 
fitted with 0.5 g load cell in Texture Profile Analysis 
(TPA) mode. Formulations were transferred at 37 °C 
into jacketed glass vials 20 mL. In this, an analytical 
probe (TA3/100) was compressed twice for each 
sample at a specified speed 2 mm/sec allowing a 
delay period 15sec from the end of the first 
compression to the start of the second. Mechanical 
parameters (hardness, compressibility, adhesiveness, 
cohesiveness and elasticity) were obtained from the 
resulting force-time curve and calculated[22]. At least 
three experiments were conducted.  
Mucoadhesion studies 
A tensile test was used to evaluate the 
mucoadhesive properties of the various formulations, 
where the measurement of maximum force, 
mucoadhesion as well as work of adhesion required 
to detach the formulations from a mucosal tissue was 
evaluated. Mucosal tissue was collected from freshly 
sacrificed animals in the slaughterhouse and 
separated from the underlying tissues, washed, cut 
into smaller parts and thoroughly rinsed. Using the 
Brookfield texture analyzer fitted with a 5 kg load 
cell, the mucoadhesive characteristics of 
formulations were assessed. Cyanoacrylate glue was 
used to attach sections (> 2 mm in thickness) taken 
from the inner part of the mucosal membrane surface 
to the reduced end of the texture analyser sample (10 
mm in diameter). The gels have been packed into a 
holder and kept at 37°C. The probe holding the 
mucosa was lowered to the gel surface at a steady 
velocity of 0.1 mm/s until a contact force of 0.05N 
was applied for 2 min in contact with the gel surface. 
The probe was then shifted vertically up at a constant 
velocity of 0.1 mm/s and the resulting force distance 
graph determined the maximum detachment force 
(F) and the area under the curve (AUC, called the 
mucoadhesion). The work of mucoadhesion (Work, 
mJ cm-2) was calculated from the following equation: 
Work =AUC 
 πr2 
where, πr2 = the gel-contacted mucosal surface.  
All analyzes have been repeated at least three times 
[23]. 
In vitro drug release and release kinetics.  
Studies of in vitro drug release were 
conducted using a dialysis bag in altered USP 
dissolution device I (Veego, DT50, India) in Simulated 
Vaginal Fluid (SVF) at pH 4.5. The dialysis bag 
(Himedia DM 50 membrane, molecular size cut off 12 
to 14 KD, pore diameter, 2.4 nm which was earlier 
soaked overnight in simulated, a precise quantity 2 
mL of in situ gelling formulation was placed. Both the 
dialysis bag ends were attached to the dissolution 
assembly basket rod. The bags were immersed at 37 
± 0.5 ° C with a stirring rate of 50 RPM in the 100 mL 
dissolution medium (Simulated Vaginal Fluid pH 4.5). 
The dissolution medium was removed at a specific 
interval and the release of the drug was evaluated at 
318 nm by the UV spectrophotometer (JASCO UV 
spectrophotometer V630). In order to maintain the 
sink condition, the same amount of dissolution 
medium was substituted in the flask. The release of 
drugs was demonstrated as the average of three 
studies. The drug release kinetic models were 
implemented using disso software to determine the 
mechanism of drug release from in situ gelling 
formulations. To determine the values of the 
correlation coefficient, the drug release data were 
attached to zero order, first order, Higuchi matrix, 
and Korsmeyer-Peppas models[24]. 
Microbiological studies 
The microbiological studies were carried out 
on the optimized formulation, Marketed formulation 
(Metrogyl Gel – Metronidazole gel) and 0.75% w/v 
drug solution for comparison against micro-
organism. Staphylococcus aureus and E. coli were 
used as the test microorganism. The petriplate was 
permitted to solidify a layer of nutrient agar 30 mL 
seeded with the test micro-organism 0.2 mL. Using a 
4 mm diameter sterile borer, cups were produced on 
the solidified agar layer. Then quantity of 
formulations comprising equal quantity of 
medication (optimized formulation and plain drug 
solution) was poured into the cups. The plates were 
incubated at 37°C for 24 h after maintaining 
petriplates at room temperature for 4 h. The zone of 
inhibition was recorded. An antibiotic zone finder 
will measure the diameter of zone of inhibition[25,26]. 
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Irritation test (Hen’s Egg Test-chorioallantoic 
membrane test)  
Modified Hen's Egg Test-Chorioallantoic 
membrane (HET-CAM) test was performed [27].The 
HET-CAM has been shown to be a method of 
evaluating the probable irritation of specific 
chemicals. The prospective irritation of compounds 
identified after exposure to test chemicals by 
observing negative alterations that happen in the 
egg's chorionallantoic membrane. Briefly, eggs from 
the poultry farm were collected from fertilized hen. 
Three eggs have been chosen for each formula 
weighing between 50 and 55 g. These eggs were 
incubated for 3 days at a temperature of 37 ° C ± 0.5 ° 
C in a humidified incubator. On 3rd day, egg albumin 3 
mL was removed from the pointing end of the egg 
using sterile techniques. The hole was sealed with the 
assistance of heated spatula by using 70 % alcohol 
sterilized parafilm (American Can Company, USA). 
The eggs were held away in the equatorial position 
for CAM growth in the shell. On the 5th day of 
incubation, the eggs were candled and every day, 
non-viable embryos were removed. 
Formulations were directly instilled on the 
CAM surface on the 10th day and left in touch for 5 
min. For vascular harm, the membrane was examined 
and the time taken to happen for injury was reported. 
It was found practically non-irritating, a 0.9 
% NaCl solution was used as a control. The results 
were recorded by the scoring scheme which is shown 
in (Table 2)[17]. 
Table 2: Scoring scheme for HET-CAM test 
Observation Score Conclusion 
No visible hemorrhage 0 Nonirritant 
Just visible membrane discoloration 1 Mild irritant 
Structures are converted partially due to membrane 
discoloration or hemorrhage 
2 Moderately irritant 
Structures are converted totally due to membrane 
discoloration or hemorrhage 
3 Severe irritant 
RESULTS AND DISCUSSION 
Drug excipient compatibility study 
Interaction studies were conducted to verify any interaction between components of the formulation. 
UV spectra were discovered to be identical before and after autoclaving. Identical graph of UV shows no 
interaction. 
The FT-IR spectra of TNZ, physical mixture of all excipients and TNZ loaded in situ formulations are 
shown in (Fig. 1-5) respectively. FT-IR spectrum of TNZ showed characteristic peaks at 3000 cm-1- 2913 cm-1 
(C-H stretching), 1759 cm-1 (C=C imidazole ring), 1522.5cm-1 (C=N imidazole ring), 1456 and 1371 cm-1 (N=O 
stretching), 1289 cm-1 (S=O stretching), 1262cm-1 (C-O stretching)(Fig. 1). IR spectrum of poloxamer 407 was 
shown characteristic peaks at 3000cm-1 to 2900 cm-1(C-H stretch aliphatic), 1345 cm-1 to 1355 cm-1 (O-H 
bending), and nearby 1100 cm-1 (C-O stretch). IR spectrum of Carbopol941NF has shown peaks at broad peak 
above 3000 cm-1(O-H stretching), nearby 1700 cm-1 (carboxyl group)where, FT-IR spectrum of HPMC E100 
showed characteristic peaks at 1729 cm-1 C=O (ester) stretching, which was the same in formulation loaded in 
situ of TNZ. Thus, there was no drug-excipient interaction. 
Appearance, clarity, pH and drug content 
All formulations were observed visually for transparency, they didn’t show any precipitation. The 
refractive gel index ranges from 1.335 to 1.337, which proves gel transparency. The pH of formulations was 
reported to be between 4.20±0.05 and 5.03±0.05. This range of pH is appropriate to the vaginal cavity since the 
vaginal pH is within the range. The percent drug content of formulation was found in range of 95.9+0.34 to 
104.1±0.25% respectively. 
Gelling Temperature  
Tgel is the temperature at which the liquid phase makes a transition to gel. An ideal in situ gel should be 
a free flowing liquid at room temperature so as to allow reproducible administration into the site of application 
where it undergoes in situ phase transition to form a strong gel. The human vaginal temperature is 37.2°C, So 
Tgel of vaginal thermo reversible gels were considered to be suitable if they were in the range of 25-37°C[17]. If 
Tgel is higher than 37°C, a liquid dosage form still exists at vaginal temperature, resulting in drainage of the 
formula from the vagina at an early stage. The gelling temperature of all batches was found in range of 37.0-
38.0°C. 
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Viscosity 
Shear thinning (reduction in viscosity with growing shear rate) in liquid as well as gel state owing to the 
pseudoplastic behavior of the gels. A Brookfield Viscometer was used to determine the viscosities of TNZ 
formulations at 25°C and at 37°C. (Fig. 6) showed the findings. Figure depicts that viscosity at 25°C is less 
compared to viscosity at 37°C because as temperature increases the formulation is convert into gel so the 
viscosity also increases. 
Spredability 
The spreadability plays a significant role in accordance with patients and helps to uniform application 
of gel to the skin. High spreadability of gel requires less time to spread and it will easily spread on mucosal 
membrane. The spreadability is the distance travelled by the formulations before the transition to gel. The rise 
in the concentration of poloxamer reduced the spreadability of formulations owing to a reduction in the 
temperature of gelation.  
Summary of various parameters like appearance, pH, drug content, gelling temperature, viscosity and 
spreadability is depicted in (Table 3). From the various parameters which are mentioned in (Table 3) we 
selected two batches i.e. PH2 and PC2 for further evaluation as these batches gave satisfactory results. These 
formulations having favorable pH range as well as converts into the gel at 37 °C. Also, PH2 and PC2 having 
moderate spreadability therefore, it can easily spread on the surface. 
Table 3: Evaluation parameter of formulations 
Batch 
no 
Appearance* pH 
Drug content 
(%) 
Gelling 
Temp (°C) 
Viscosity at 
25°C (cps) 
Viscosity at 
37°C (cps) 
Spredability 
(mm) 
PH1 ++ 4.20±0.05 99.8±1.12 37.3 1100 4800 17 
PH2 ++ 4.48±0.1 102.2±0.5 37.0 1200 5200 15 
PH3 ++ 4.56±0.2 97.4±0.31 36.6 1250 5300 14 
PC1 ++ 4.45±0.1 104.1±0.25 38.0 1890 6000 20 
PC2 ++ 4.62±0.05 100.2±0.18 37.0 2000 6400 18 
PC3 ++ 5.03±0.05 95.9±0.34 37.0 2050 6530 16 
*turbid(-), slightly turbid (+), clear and transparent (+ +) 
Mechanical Properties of Polymer Solutions 
Texture profile analysis (TPA) is a mechanical test that defines the compressive stress and subsequent 
relaxation strength of pharmaceutical formulations. TPA offers data on the impacts of repeated shearing stress 
on formulations structural characteristics, a property called ‘cohesiveness’. Optimized gel formulation 
containing HPMC and carbopol i.e. PH2 and PC2were tested for TPA.  
Hardness is defined as the force required to achieve a deformation (Strength Unit, N). The 
compressibility determines the work required to deform the material during the first contraction of the probe 
(work unit, N mm). The adhesiveness of the formulation is the job needed to resolve the attractive forces 
between the surface of the sample and the surface of the probe. This parameters helped to understand 
performance of the formulation are viz. ease of application to the surface or from container and retention of gel 
on site of application. The textural properties of TNZ in situ gel formulations are shown in (Table 4). 
Table 4: Mechanical properties of in situ gel of TNZ 
Batch no 
Hardness (N) 
± SD 
Compressibility 
(N.mm) ± SD 
Adhesiveness 
(N.mm) ± SD 
Elasticity ± 
SD 
Cohesiveness 
± SD 
PH2 - 20⁰C 0.012 ± 0.000 0.025 ± 0.001 0.038 ± 0.002 0.800 ± 0.036 0.574 ± 0.069 
PC2 - 20⁰C 0.009 ± 0.006 0.089 ± 0.058 0.035 ± 0.006 0.752 ± 0.009 0.155 ± 0.012 
PH2 - 37⁰C 0.374 ± 0.053 0.720 ± 0.000 0.765 ± 0.013 1.752 ± 0.029 1.00 ± 0.033 
PC2 - 37⁰C 0.204 ± 0.025 0.557 ± 0.003 0.40 ± 0.036 1.102 ± 0.025 0.682 ± 0.003 
Mucoadhesion Studies 
Quantification of mucoadhesion is essential in order to guarantee that the adhesion provided by 
formulations is adequate to assure prolonged retention at the application site, but not excessively, because may 
result in harm to the mucous membrane. Mucoadhesion study gives the thorough assessment of the 
detachment phenomenon of various formulations under examination, formulation PH2 (containing 20% 
poloxamer 407 and HPMC) is having highest mucoadhesion as compared to the formulation containing 
carbopol. The results are shown in the following graph (Fig. 7). 
Shital R. Nikhar et al. Thermosensitive in Situ Gel of Tinidazole in Treatment of Bacterial Vaginosis 
     IJAPR | January 2020 | Vol 8 | Issue 1  7 
In vitro release kinetics 
The formulations of in situ gelling revealed a biphasic pattern of release, an original burst release 
accompanied by the continued release of TNZ. TNZ's burst release at the beginning of dissolution signaled a 
delay in sol transition to gel. Continued release of drug further stated the slower diffusion of drug from the gel 
matrix. This will confirm the controlled release behavior of the formulation. The original burst release is useful 
as it helps to achieve the drug's therapeutic concentration in a minimum of moment followed by steady release 
to retain the sustained release of a drug.  
Developed formulation PH2 showed 30.5% cumulative drug release after 1 h 53.60% after 4 h and 
71.3% after 8 h and PC2 showed 39.08% cumulative drug release after 1h 62.44% after 4 h and 71.7% after 8 h 
(Fig 8). Burst effect might be due to initial migration of the drug toward the surface of the matrix. The release 
kinetics data is shown in (Fig 8) (Table 5). The formulation obeys the Higuchi matrix model i.e. it will indicate 
that initial drug concentration in the matrix is much higher than drug solubility and perfect sink conditions are 
always attained in the release environment. 
Table 5: Release kinetics of in situ gel of TNZ 
Batch no 
Regression coefficient (R2) 
Zero order First order Higuchi matrix Korsemeyer Peppas Hixoncrowell 
PH2 0.9035 0.9687 0.9931 0.9559 0.9515 
PC2 0.7887 0.8769 0.9465 0.8882 0.8504 
Microbiological studies 
The antimicrobial activity of the formulation was tested against the strains E coli and S aureous by using 
the cup plate technique. Here in the study comparison of the formulation was done against the marketed 
formulation and plane drug solution. The zone of inhibition of PH2 and PC2 batches was given in the (Table 6) 
(Fig. 9 and Fig. 10) respectively. This indicated that the formulations showed greater activity than the marketed 
formulation. 
Table 6: Zone of inhibition of optimized batches 
 Zone of inhibition(mm) 
 
Standard Marketed Formulation Formulation 
E coli 
PH2 30 28 31 
PC2 35 28 34 
S. aureous 
PH2 32 20 31 
PC2 34 25 34 
Irritation test 
Irritation test of the developed formulation was carried out by Hen's egg CAM test. It is a fast, delicate 
and cheap test. Incubated egg testing is a borderline event between in vivo and in vitro processes and does not 
conflict with ethical and legal requirements. Using this method, developed formulations were tested and the 
result contrasted with normal saline, which was used as a control that is intended to be non-irritating because 
0 score was obtained for normal saline. 
As PH2 batch have shown consistent better mucoadhesive as well as better in vitro release, hence it was 
selected for the study of Irritation test on hen’s eggs. The optimized formulation PH2 was tested for irritation 
study and was found to be non-irritant up to 1 h (mean score 0), with a mean score of 0.66 up to 24 h as 
depicted in (Table 7). 
Table 7: HET CAM ASSAY observations 
Sample 
 
HET- CAM Score 
Time in min 
0 5 15 30 60 120 240 480 1440 
Control 0 0 0 0 0 0 0 0 0 
Formulation  
Egg 1 0 0 0 0 0 0 0 0 0 
Egg 2 0 0 0 0 0 0 0 0 1 
Egg3 0 0 0 0 0 0 0 1 1 
Mean 0 0 0 0 0 0 0 0.33 0.66 
*0 Non irritant, 1 Mild irritant 
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CONCLUSION 
This research outlined formulations of in situ 
gel of TNZ and assessed their rheological and textural 
characteristics. Polaxomer possesses low 
mucoadhesive characteristics, but its thermal 
sensitivity makes it simple to apply and cover the 
mucosa. Adding HPMC / Carbopol to the formula it 
decreased the temperature of the sol-gel transition 
and influenced the mucoadhesive and mechanical 
properties of formulation. 
The results obtained from the texture 
characterization of 20% polaxomer and 0.5% HPMC 
E100 i.e. PH2 formulation showed the better 
mechanical properties as well as good mucoadhesive 
strength. This formulation also gives sustained drug 
release for 7 h. Although the PC2 Formulation having 
the good antimicrobial activity than the PH2 
formulation but other factors are better in case of 
PH2 formulation. From the all observations and 
based on maximum desirability and cost 
effectiveness, in situ vaginal gel containing 20% 
polaxomer and 0.5% HPMC E100 could be 
considered as a highly promising treatment for 
bacterial vaginosis. Our findings have shown that the 
formulations created have been discovered worthy 
for further study. 
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Figures 
 
Figure 1: FTIR spectrum of TNZ (pure drug) 
 
Figure 2: FTIR spectrum of physical mixture of polaxomer 407, HPMC E100 and TNZ 
 
Figure 3: FTIR spectrum of physical mixture of polaxomer 407, carbopol 941NF and TNZ 
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Figure 4: FTIR spectrum of in situ gel containing polaxomer 407 and HPMC E100 
 
Figure 5: FTIR spectrum of in situ gel containing polaxomer 407 and 1657carbopol 941NF 
 
Figure 6: Results of viscosity 
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Figure 7: Mucoadhesive strength of formulation 
 
Figure 8: In vitro release of formulation 
 
Figure 9: Zone of inhibition of optimized formulation PH2 
 
Figure 10: Zone of inhibition of optimized formulation PC2 
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